Soluble guanylate cyclase redox state under hypoxia or hypoxia/ reoxygenation in isolated monkey coronary arteries

Journal of Pharmacological Sciences

Volumn 125, Issue 2, 2014, Pages 169-175

  Tawa, Masashi ^a   Geddawy, Ayman ^a,b   Shimosato, Takashi ^a   Iwasaki, Hirotaka ^a   Imamura, Takeshi ^a   Okamura, Tomio ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Minia University   (Egypt)

Author keywords

cGMP; Coronary artery; Hypoxia; Reoxygenation; Soluble guanylate cyclase

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; BAY 60 2770; CYCLIC GMP; GUANYLATE CYCLASE; TEMPOL; UNCLASSIFIED DRUG; VASODILATOR AGENT; 3-(4-AMINO-5-CYCLOPROPYLPYRIMIDINE-2-YL)-1-(2-FLUOROBENZYL)-1H-PYRAZOLO(3,4-B)PYRIDINE; 4-(((4-CARBOXYBUTYL) (2- (5-FLUORO-2-((4'-(TRIFLUOROMETHYL) BIPHENYL-4-YL)METHOXY)PHENYL)ETHYL) AMINO)METHYL)BENZOIC ACID; BENZOIC ACID DERIVATIVE; BIPHENYL DERIVATIVE; FLUORINATED HYDROCARBON; NITRIC OXIDE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SUPEROXIDE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; HYPOXIA; NONHUMAN; NUCLEIC ACID ANALYSIS; OXIDATION REDUCTION STATE; REOXYGENATION; VASODILATATION; ANIMAL; ANOXIA; ANTAGONISTS AND INHIBITORS; CORONARY BLOOD VESSEL; DRUG EFFECTS; ENZYMOLOGY; FEMALE; IN VITRO STUDY; MACACA; MALE; METABOLISM; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; SOLUBILITY;

ANIMALS; ANOXIA; BENZOATES; BIPHENYL COMPOUNDS; CORONARY VESSELS; CYCLIC GMP; FEMALE; GUANYLATE CYCLASE; HYDROCARBONS, FLUORINATED; IN VITRO TECHNIQUES; MACACA; MALE; NITRIC OXIDE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PYRAZOLES; PYRIDINES; SOLUBILITY; SUPEROXIDE DISMUTASE; SUPEROXIDES; VASODILATION;

EID: 84903994936     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.14046FP     Document Type: Article

References (31)

1. Berne RM. Regulation of coronary blood flow. Physiol Rev. 1964;44:1-29.
2. Richard V, Kaeffer N, Tron C, Thuillez C. Ischemic preconditioning protects against coronary endothelial dysfunction induced by ischemia and reperfusion. Circulation. 1994;89:1254-1261. (Pubitemid 24076553)
3. Calderón-Sánchez E, Fernández-Tenorio M, Ordóñez A, López-Barneo J, Ureña J. Hypoxia inhibits vasoconstriction induced by metabotropic Ca2+ channel-induced Ca2+ release in mammalian coronary arteries. Cardiovasc Res. 2009;82:115-124.
4. Mingone CJ, Gupte SA, Iesaki T, Wolin MS. Hypoxia enhances a cGMP-independent nitric oxide relaxing mechanism in pulmonary arteries. Am J Physiol Lung Cell Mol Physiol. 2003;285:L296-L304. (Pubitemid 36909445)
5. Rubanyi G, Paul RJ. O2-sensitivity of beta adrenergic responsiveness in isolated bovine and porcine coronary arteries. J Pharmacol Exp Ther. 1984;230:692-698. (Pubitemid 14040391)
6. Vedernikov YP, Gräser T, Leisner H, Tiedt N. Effect of hypoxia on endothelium-dependent relaxation of porcine coronary arteries and veins. Biomed Biochim Acta. 1991;50:257-263.
7. Hashimoto M, Close LA, Ishida Y, Paul RJ. Dependence of endothelium-mediated relaxation on oxygen and metabolism in porcine coronary arteries. Am J Physiol. 1993;265:H299-H306. (Pubitemid 23224724)
8. Fukuda S, Toriumi T, Xu H, Kinoshita H, Nishimaki H, Kokubun S, et al. Enhanced beta-receptor-mediated vasorelaxation in hypoxic porcine coronary artery. Am J Physiol. 1999;277:H1447-H1452. (Pubitemid 29522675)
9. Tawa M, Yamamizu K, Geddawy A, Shimosato T, Imamura T, Ayajiki K, et al. Impairment by hypoxia or hypoxia/reoxygenation on nitric oxide-mediated relaxation in isolated monkey coronary artery: the role of intracellular superoxide. J Pharmacol Sci. 2011;116:188-196.
10. Denninger JW, Marletta MA. Guanylate cyclase and the NO/ cGMP signaling pathway. Biochim Biophys Acta. 1999;1411:334-350. (Pubitemid 29221959)
11. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin- 1-one. Mol Pharmacol. 1995;48:184-188.
12. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S AK, Meurer S, et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest. 2006;116:2552-2561. (Pubitemid 44330154)
13. Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006;5:755-768. (Pubitemid 44323702)
14. Zhou Z, Pyriochou A, Kotanidou A, Dalkas G, van Eickels M, Spyroulias G, et al. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. Am J Physiol Heart Circ Physiol. 2008;295:H1763-H1771.
15. Chester M, Seedorf G, Tourneux P, Gien J, Tseng N, Grover T, et al. Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2011;301:L755-L764.
16. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123:2263-2273.
17. Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol. 2009;191: 277-308.
18. Schmidt HH, Schmidt PM, Stasch JP. NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol. 2009;191:309-339.
19. Matsumoto T, Okamura T, Kinoshita M, Toda N. Interactions of nitrovasodilators and atrial natriuretic peptide in isolated dog coronary arteries. Eur J Pharmacol. 1993;237:31-37. (Pubitemid 23181236)
20. Toda N, Matsumoto T, Yoshida K. Comparison of hypoxia- induced contraction in human, monkey, and dog coronary arteries. Am J Physiol. 1992;262:H678-H683.
21. Wolin MS, Gupte SA, Oeckler RA. Superoxide in the vascular system. J Vasc Res. 2002;39:191-207. (Pubitemid 34827787)
22. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986;320:454-456. (Pubitemid 16097810)
23. Gerassimou C, Kotanidou A, Zhou Z, Simoes DC, Roussos C, Papapetropoulos A. Regulation of the expression of soluble guanylyl cyclase by reactive oxygen species. Br J Pharmacol. 2007;150:1084-1091. (Pubitemid 46625092)
24. Azumi H, Inoue N, Ohashi Y, Terashima M, Mori T, Fujita H, et al. Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris: important role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol. 2002;22: 1838-1844. (Pubitemid 35315770)
25. Guzik TJ, Sadowski J, Guzik B, Jopek A, Kapelak B, Przbylowski P, et al. Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol. 2006;26:333-339. (Pubitemid 43732196)
26. Jackson WF, Busse R. Elevated guanosine 3′:5′-cyclic monophosphate mediates the depression of nitrovasodilator reactivity in endothelium-intact blood vessels. Naunyn Schmiedebergs Arch Pharmacol. 1991;344:345-350.
27. Bina S, Hart JL, Sei Y, Muldoon SM. Factors contributing to differences in the regulation of cGMP in isolated porcine pulmonary vessels. Eur J Pharmacol. 1998;351:253-260. (Pubitemid 28312938)
28. Toyoshima H, Nasa Y, Hashizume Y, Koseki Y, Isayama Y, Kohsaka Y, et al. Modulation of cAMP-mediated vasorelaxation by endothelial nitric oxide and basal cGMP in vascular smooth muscle. J Cardiovasc Pharmacol. 1998;32:543-551. (Pubitemid 28440955)
29. Priviero FB, Baracat JS, Teixeira CE, Claudino MA, De Nucci G, Antunes E. Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator. Clin Exp Pharmacol Physiol. 2005;32:728-734. (Pubitemid 41603152)
30. Close LA, Bowman PS, Paul RJ. Reoxygenation-induced relaxation of coronary arteries. A novel endothelium-dependent mechanism. Circ Res. 1994;74:870-881. (Pubitemid 24121590)
31. Fukuda S, Sakuma K, Tsukui A, Fujiwara N, Tanaka T, Fujihara H, et al. Hypoxia modifies the vasodilatory effects of nitroglycerin, prostaglandin E1, and hydralazine on isolated porcine coronary arteries. J Cardiovasc Pharmacol. 1994;23:852-858. (Pubitemid 24127505)